Navigation Links
Questcor Proxy Proposals All Approved at 2011 Shareholder Meeting
Date:5/20/2011

ANAHEIM, Calif., May 20, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced the passage by its shareholders of the six proposals considered during the Company's annual meeting on May 19, 2011.

Shareholders voted in favor of the following:

  • All six nominees for the Board of Directors;
  • "Say-on-pay" advisory vote on executive officer compensation;
  • Advisory vote with respect to the frequency of future "say-on-pay" votes (once every year);
  • Amendment to the Company's 2006 Equity Incentive Award Plan, increasing the number of available shares of Questcor common stock by 3,500,000 shares;
  • Amendment to the Company's 2003 Employee Stock Purchase Plan, increasing the number of shares available for issuance by 600,000 shares; and
  • The retention of BDO USA, LLP as the Company's independent registered public accounting firm for the year ending December 31, 2011.

"On behalf of the board of directors, management and employees of Questcor, I would like to thank our shareholders for their support of the proposals considered at this year's annual meeting.  We believe that our shareholders' approval of the proposals to add shares to our Equity Incentive Award Plan and our Employee Stock Purchase Plan will play a key role in Questcor's ability to attract top talent to the organization and continue to generate strong returns for our shareholders," said Don M. Bailey, President and CEO of Questcor.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Our reliance on Acthar for substantially all of our net sales and profits;
  • Our ability to generate revenue from sales of Acthar to treat on-label indications associated with NS, and our ability to develop other therapeutic uses for Acthar;
  • Our ability to effectively manage our growth and our reliance on key personnel;
  • Volatility in Questcor's monthly and quarterly Acthar shipments and end-user demand, as well as volatility in our stock price; and
  • Other risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2010, and other documents filed with the Securities and Exchange Commission.

For more information, please visit www.questcor.com or www.acthar.com.  


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Discusses ISS Proxy Recommendations; Provides Business Update
2. Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011
3. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011
4. Questcor Pharmaceuticals to Present at the Needham Healthcare Conference
5. Questcor Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
6. Questcor Pharmaceuticals Selects BDO USA as its Auditor
7. Questcor Reports 2010 Financial Results
8. Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011
9. Questcor Pharmaceuticals Reports Strong Finish to 2010
10. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011
11. Questcor Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... 2016 Mast Therapeutics, Inc. (NYSE ... for sickle cell disease and heart failure, today announced ... units at a price to the public of $0.275 ... the Company,s common stock and one warrant to purchase ... exercise price of $0.42 per share. The warrants are ...
(Date:2/10/2016)... 10, 2016 ALSP, Inc. announced that it has ... for Medical Affairs in preparation for its move into clinical ... PhD, CEO, stated, "We are pleased to welcome Dallas ... working with an individual of such practical knowledge and far-reaching ... drawing deeply on his broad experience and success as a ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 10, 2016 , ... Gout is like no other joint pain. It strikes ... with intense swelling and redness. It is triggered by the crystallization of uric acid ... the most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. ...
(Date:2/10/2016)... ... 10, 2016 , ... AHRA: The Association for Medical Imaging ... Fox will serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s ... more effectively communicate with their own organizational staff and leadership. , “I ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the ... a solution that ensures the integrity of biological samples while operating at ultra-high ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Workrite Ergonomics, who ... that has evolved from humble beginnings to being an internationally recognized leader in their ... we are today”, said Charlie Lawrence, President of Workrite. “Workrite recognized the importance ...
Breaking Medicine News(10 mins):